Italia markets open in 6 hours 56 minutes

Immutep Limited (IMMP)

NasdaqGM - NasdaqGM Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
2,2000-0,0600 (-2,65%)
Alla chiusura: 04:00PM EDT
2,2111 +0,01 (+0,50%)
Dopo ore: 04:06PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente2,2600
Aperto2,2500
Denaro2,1700 x 100
Lettera2,2400 x 100
Min-Max giorno2,1500 - 2,3300
Intervallo di 52 settimane1,5000 - 3,9000
Volume266.539
Media Volume138.067
Capitalizzazione261,543M
Beta (5 anni mensile)1,83
Rapporto PE (ttm)N/D
EPS (ttm)-0,2500
Prossima data utiliN/D
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A7,50
  • GlobeNewswire

    Immutep Announces Publication of Abstracts at ESMO Congress 2023

    Media Release New updated data from TACTI-002, including more mature Overall Survival data, will be presented during the Mini Oral session on Saturday, October 21st, at 9:05 CESTImmutep to host webcast to discuss ESMO 2023 clinical data on Monday, October 23rd, at 8AM AEDT (Sunday, October 22nd, at 5PM ET) SYDNEY, AUSTRALIA, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immuno

  • GlobeNewswire

    Immutep Announces Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

    Media Release SYDNEY, AUSTRALIA, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease, today announces an abstract has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2023, taking place in San Diego, California and virtually from 1 to 5 November 2023. Presentation DetailsTitle: Biomarke

  • GlobeNewswire

    Commercial Manufacturing of Eftilagimod Alpha at 2000L Scale Granted Authorization for Clinical Trial Use

    Comparability of Drug Substance and Drug Product manufactured at 2,000L scale achievedMedia Release SYDNEY, AUSTRALIA, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces the regulatory authorization of eftilagimod alpha (“efti”) manufactured at commercial 2,000L scale for use in clinical trials across multiple Euro